Biomarkers /
BRAF V600E
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
BRAF V600E is a predictive biomarker for use of dabrafenib, vemurafenib, trametinib, encorafenib, cetuximab, cobimetinib, panitumumab, binimetinib, cemiplimab, imatinib, and pembrolizumab in patients.
Of the therapies with BRAF V600E as a predictive biomarker, 9 are FDA-approved and 10 have NCCN guidelines in at least one clinical setting.
Melanoma, colorectal carcinoma, non-small cell lung carcinoma, ganglioglioma, and pilocytic astrocytoma have the most therapies targeted against BRAF V600E or its related pathways [5].
Cetuximab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: May Decrease Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
Dabrafenib +
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, BNF, SMC) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, SMC) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy with dabrafenib is recommended, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Thyroid Gland Follicular Carcinoma -
Thyroid Gland Papillary Carcinoma -
Imatinib +
Gastrointestinal Stromal Tumor -
Panitumumab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: May Decrease Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor. |
Trametinib +
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Trametinib is FDA approved for single-agent use to treat patients with unresectable or metastatic melanoma with BRAF V600E/K; however, trametinib monotherapy is no longer an NCCN-recommended treatment option due to relatively poor efficacy compared with BRAF inhibitor monotherapy and BRAF/MEK inhibitor combination therapy. |
Vemurafenib +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (MCG) |
Hairy Cell Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Hairy Cell Leukemia, a subtype of Mature B-Cell Lymphoma/Leukemia, harboring BRAF V600E mutation responded to vemurafenib in two patients who had refractory disease or were in relapse after conventional therapies. |
Mature B-Cell Lymphoma/Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Hairy Cell Leukemia (HCL), a subtype of Mature B-Cell Lymphoma/Leukemia harboring BRAF V600E mutation responded to vemurafenib in two patients who had refractory disease or were in relapse after conventional therapies. |
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, single-agent vemurafenib is an option if the combination of dabrafenib + trametinib is not tolerated. |
Thyroid Gland Follicular Carcinoma -
Thyroid Gland Papillary Carcinoma -
Binimetinib + Encorafenib +
Melanoma -
Cetuximab + Encorafenib +
Colorectal Carcinoma -
Cobimetinib + Vemurafenib +
Ganglioglioma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity |
Pilocytic Astrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Pleomorphic Xanthoastrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Dabrafenib + Trametinib +
Cholangiocarcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended for subsequent line treatment. |
Ganglioglioma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Melanoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity. |
Non-Small Cell Lung Carcinoma -
Pilocytic Astrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Pleomorphic Xanthoastrocytoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment. |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma -
Encorafenib + Panitumumab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely, unless given with a BRAF inhibitor |
Clinical Trials
BRAF V600E serves as an inclusion eligibility criterion in 97 clinical trials, of which 71 are open and 26 are closed. Of the trials that contain BRAF V600E as an inclusion criterion, 1 is early phase 1 (1 open), 25 are phase 1 (17 open), 20 are phase 1/phase 2 (17 open), 44 are phase 2 (30 open), and 7 are phase 3 (6 open).
Trials with BRAF V600E in the inclusion eligibility criteria most commonly target melanoma, non-small cell lung carcinoma, colorectal carcinoma, malignant solid tumor, and multiple myeloma [5].
Trametinib, dabrafenib, encorafenib, binimetinib, and pembrolizumab are the most frequent therapies in trials with BRAF V600E as an inclusion criteria [5].
Significance of BRAF V600E in Diseases
Melanoma +
BRAF V600E is an inclusion criterion in 47 clinical trials for melanoma, of which 29 are open and 18 are closed. Of the trials that contain BRAF V600E and melanoma as inclusion criteria, 17 are phase 1 (9 open), 12 are phase 1/phase 2 (9 open), 16 are phase 2 (10 open), and 2 are phase 3 (1 open) [5].
Dabrafenib, vemurafenib, binimetinib, encorafenib, cobimetinib, and trametinib have evidence of efficacy in patients with BRAF V600E in melanoma [5].
Colorectal Carcinoma +
BRAF V600E is an inclusion criterion in 12 clinical trials for colorectal carcinoma, of which 7 are open and 5 are closed. Of the trials that contain BRAF V600E and colorectal carcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (3 open), and 2 are phase 3 (2 open) [5].
Cetuximab, encorafenib, and panitumumab have evidence of efficacy in patients with BRAF V600E in colorectal carcinoma [5].
Non-Small Cell Lung Carcinoma +
BRAF V600E is an inclusion criterion in 12 clinical trials for non-small cell lung carcinoma, of which 7 are open and 5 are closed. Of the trials that contain BRAF V600E and non-small cell lung carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 6 are phase 2 (3 open) [5].
Dabrafenib, trametinib, pembrolizumab, and vemurafenib have evidence of efficacy in patients with BRAF V600E in non-small cell lung carcinoma [5].
Hairy Cell Leukemia +
BRAF V600E is an inclusion criterion in 4 clinical trials for hairy cell leukemia, of which 4 are open and 0 are closed. Of the trials that contain BRAF V600E and hairy cell leukemia as inclusion criteria, 4 are phase 2 (4 open) [5].
Vemurafenib has evidence of efficacy in patients with BRAF V600E in hairy cell leukemia [5].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
BRAF V600E is an inclusion criterion in 4 clinical trials for thyroid gland undifferentiated (anaplastic) carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BRAF V600E and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].
Dabrafenib and trametinib have evidence of efficacy in patients with BRAF V600E in thyroid gland undifferentiated (anaplastic) carcinoma [5].
Thyroid Gland Papillary Carcinoma +
BRAF V600E is an inclusion criterion in 3 clinical trials for thyroid gland papillary carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF V600E and thyroid gland papillary carcinoma as inclusion criteria, 3 are phase 2 (2 open) [5].
Dabrafenib and vemurafenib have evidence of efficacy in patients with BRAF V600E in thyroid gland papillary carcinoma [5].
Cholangiocarcinoma +
BRAF V600E is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF V600E and cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Dabrafenib and trametinib have evidence of efficacy in patients with BRAF V600E in cholangiocarcinoma [5].
Pilocytic Astrocytoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF V600E in pilocytic astrocytoma [5].
Thyroid Gland Follicular Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Dabrafenib and vemurafenib have evidence of efficacy in patients with BRAF V600E in thyroid gland follicular carcinoma [5].
Ganglioglioma +
Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF V600E in ganglioglioma [5].
Mature B-Cell Lymphoma/Leukemia +
Vemurafenib has evidence of efficacy in patients with BRAF V600E in mature B-cell lymphoma/leukemia [5].
Pleomorphic Xanthoastrocytoma +
Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF V600E in pleomorphic xanthoastrocytoma [5].
Malignant Solid Tumor +
BRAF V600E is an inclusion criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain BRAF V600E and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].
Multiple Myeloma +
BRAF V600E is an inclusion criterion in 6 clinical trials for multiple myeloma, of which 5 are open and 1 is closed. Of the trials that contain BRAF V600E and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (4 open) [5].
Cutaneous Melanoma +
BRAF V600E is an inclusion criterion in 5 clinical trials for cutaneous melanoma, of which 5 are open and 0 are closed. Of the trials that contain BRAF V600E and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 2 are phase 3 (2 open) [5].
Low Grade Glioma +
BRAF V600E is an inclusion criterion in 4 clinical trials for low grade glioma, of which 4 are open and 0 are closed. Of the trials that contain BRAF V600E and low grade glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [5].
Breast Carcinoma +
BRAF V600E is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF V600E and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].
Glioma +
BRAF V600E is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain BRAF V600E and glioma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Ovarian Carcinoma +
BRAF V600E is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF V600E and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open) [5].
Thyroid Gland Carcinoma +
BRAF V600E is an inclusion criterion in 3 clinical trials for thyroid gland carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF V600E and thyroid gland carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].
Bladder Carcinoma +
BRAF V600E is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF V600E and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Colorectal Adenocarcinoma +
BRAF V600E is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF V600E and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].
Gastrointestinal Stromal Tumor +
BRAF V600E is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BRAF V600E and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [5].
Head And Neck Carcinoma +
BRAF V600E is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRAF V600E and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].
Malignant Glioma +
BRAF V600E is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain BRAF V600E and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Melanoma Of Unknown Primary +
BRAF V600E is an inclusion criterion in 2 clinical trials for melanoma of unknown primary, of which 2 are open and 0 are closed. Of the trials that contain BRAF V600E and melanoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
BRAF V600E is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].
Ameloblastoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for ameloblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF V600E and ameloblastoma as inclusion criteria, 1 is phase 2 (0 open) [5].
Anaplastic Pleomorphic Xanthoastrocytoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bile Duct Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bronchogenic Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cancer +
BRAF V600E is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and cancer as inclusion criteria, 1 is phase 1 (1 open) [5].
Cervical Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Chronic Lymphocytic Leukemia +
BRAF V600E is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].
Colon Adenocarcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gallbladder Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Adenocarcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF V600E and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Germ Cell Tumor +
BRAF V600E is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Glioblastoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF V600E and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Head And Neck Squamous Cell Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF V600E and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Histiocytosis +
BRAF V600E is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [5].
Hodgkin Lymphoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF V600E and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Lung Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lymphoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
BRAF V600E is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Non-Hodgkin Lymphoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF V600E and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Optic Nerve Glioma +
BRAF V600E is an inclusion criterion in 1 clinical trial for optic nerve glioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and optic nerve glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Pancreatic Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Papillary Craniopharyngioma +
BRAF V600E is an inclusion criterion in 1 clinical trial for papillary craniopharyngioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and papillary craniopharyngioma as inclusion criteria, 1 is phase 2 (1 open) [5].
Poorly Differentiated Thyroid Gland Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Prostate Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Rectal Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Skin Squamous Cell Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for skin squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Small Intestinal Adenocarcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Soft Tissue Sarcoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Splenic Diffuse Red Pulp Small B-Cell Lymphoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for splenic diffuse red pulp small B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and splenic diffuse red pulp small B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thyroid Gland Squamous Cell Carcinoma +
BRAF V600E is an inclusion criterion in 1 clinical trial for thyroid gland squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E and thyroid gland squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
